Treatment of adults with multiple myeloma

THERAPEUTIC INDICATIONS

Bortega as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

Bortega in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.

Other indications find in SPC.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.

Treatment of breast cancer

THERAPEUTIC INDICATIONS

Adjuvant treatment applied in postmenopausal women with early stage of breast cancer with positive hormone receptors.

Extended adjuvant treatment of breast cancer with positive hormone receptors in postmenopausal women who already done standard adjuvant treatment for five years of Tamoxifen.

First-line of treatment of advanced breast cancer with positive hormone receptors applied in postmenopausal women.

Treatment of advanced breast cancer applied in women with natural or artificially induced menopause after relapse or disease progression which has been treated with Antiestrogens.

Neoadjuvant treatment applied in postmenopausal women with HER-2 negative breast cancer with positive hormone receptors when the chemotherapy is not appropriate and when the immediate surgery is not indicated.

In patients with hormone receptor of negative breast cancer efficacy has not been demonstrated.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.

 

Treatment of breast cancer

THERAPEUTIC INDICATIONS

Treatment of advanced breast cancer with positive hormone receptors applied in postmenopausal women.

Adjuvant treatment of early invasive breast cancer applied in postmenopausal women with positive hormone receptors.

Adjuvant treatment of early invasive breast cancer applied in postmenopausal women with positive hormone receptors, who are already treated with adjuvant Tamoxifen for 2-3 years.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.